Share Price and Basic Stock Data
Last Updated: November 10, 2025, 5:10 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
MPS Pharmaa Ltd operates in the pharmaceuticals sector, but it has reported a concerning trend in revenue generation. Notably, the company recorded zero sales across all reported quarters from June 2022 to June 2025. This stark absence of revenue highlights significant operational challenges, particularly given the industry’s competitive landscape. Historically, MPS Pharmaa’s sales peaked at ₹30.27 Cr in March 2014, but have since plummeted to ₹0.00 in the trailing twelve months (TTM). The last recorded positive revenue was just ₹0.03 Cr in March 2022, indicating a prolonged decline that raises red flags for potential investors. The company’s inability to generate sales over multiple quarters suggests a critical need for strategic re-evaluation and operational restructuring to regain market traction.
Profitability and Efficiency Metrics
The profitability metrics of MPS Pharmaa Ltd present a challenging picture, with a net loss consistently reported across the last several quarters. The net profit stood at -₹0.89 Cr for the most recent reporting period, with losses reported in every quarter since June 2022. The operating profit margin (OPM) has remained negative, reflecting ongoing inefficiencies and high operational costs relative to its nonexistent sales. The interest coverage ratio (ICR) is alarmingly low at -1433.20x, indicating substantial difficulty in meeting interest obligations from earnings. The return on equity (ROE) has also declined significantly to 59.0%, while return on capital employed (ROCE) is reported at a mere 9.79%, suggesting that the company is not efficiently utilizing its capital to generate profits. These metrics underline the urgent need for improved operational efficiency and cost management to enhance profitability.
Balance Sheet Strength and Financial Ratios
MPS Pharmaa’s balance sheet reveals a precarious financial position, marked by negative reserves of -₹18.03 Cr and borrowings amounting to ₹7.46 Cr. The total debt to equity ratio stands at an alarming 6.90, indicating that the company is heavily leveraged, which raises concerns about its long-term sustainability. The current ratio is reported at 0.25, highlighting liquidity issues, as it falls below the ideal threshold of 1. This low ratio indicates that the company may struggle to meet short-term liabilities. The book value per share has declined from ₹2.00 in March 2022 to ₹0.56 in March 2025, reflecting deteriorating asset value. Coupled with the high price-to-book value ratio of 5.63x, this suggests that the market has a pessimistic outlook on the company’s future performance, making it crucial for MPS Pharmaa to address its financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of MPS Pharmaa Ltd indicates a stable yet concerning structure. Promoters own 35.89% of the company, which has remained consistent, showing some level of commitment. However, the public holds a significant 63.53%, suggesting that retail investors dominate the shareholder base, a factor that can lead to volatility in stock performance. Institutional investment is minimal, with domestic institutional investors (DIIs) holding only 0.58%. This lack of institutional backing may reflect broader market skepticism regarding the company’s prospects. The number of shareholders has seen a slight decline from 4,529 in September 2022 to 4,445 in June 2025, indicating a potential erosion of investor confidence. The lack of significant institutional investment and the decline in shareholder numbers may hinder the company’s ability to raise capital in the future.
Outlook, Risks, and Final Insight
The outlook for MPS Pharmaa Ltd is fraught with challenges that require immediate attention. Key risks include the persistent lack of revenue, high leverage, and negative profitability metrics, which could lead to liquidity issues and operational insolvency if not addressed. The company’s reliance on debt financing, combined with its inability to generate income, poses a significant risk for both current and potential investors. Additionally, the lack of institutional support may limit its ability to attract further investment needed for a turnaround. Strengths include the stable ownership structure from promoters and a commitment to maintaining operations despite challenges. The path forward will necessitate a robust strategic plan focused on revenue generation and cost management to restore investor confidence and improve financial stability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of MPS Pharmaa Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 247/84.3 | 30.7 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,901 Cr. | 450 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.7 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.1/17.0 | 39.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,221.27 Cr | 1,192.93 | 53.76 | 199.56 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.17 | 0.24 | 0.23 | 0.31 | 0.19 | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 |
| Operating Profit | -0.17 | -0.24 | -0.23 | -0.31 | -0.19 | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 |
| OPM % | |||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.21 | -0.28 | -0.27 | -0.33 | -0.20 | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | -3.03% | -5.00% | -5.26% | -4.55% | 0.00% | -4.35% | -4.35% | 0.00% | 21.74% | -4.35% |
| Net Profit | -0.20 | -0.27 | -0.26 | -0.32 | -0.19 | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 |
| EPS in Rs | -0.10 | -0.14 | -0.14 | -0.17 | -0.10 | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 |
Last Updated: August 19, 2025, 1:05 pm
Below is a detailed analysis of the quarterly data for MPS Pharmaa Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.19 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.19 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.19 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded -0.19 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.23 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded -0.23 Cr..
- For Tax %, as of Jun 2025, the value is -4.35%. The value appears to be improving (decreasing) as expected. It has decreased from 21.74% (Mar 2025) to -4.35%, marking a decrease of 26.09%.
- For Net Profit, as of Jun 2025, the value is -0.22 Cr.. The value appears strong and on an upward trend. It has increased from -0.28 Cr. (Mar 2025) to -0.22 Cr., marking an increase of 0.06 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.12. The value appears strong and on an upward trend. It has increased from -0.15 (Mar 2025) to -0.12, marking an increase of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | -0.00 | -0.00 | 0.03 | -0.00 | -0.00 | -0.00 | 0.00 |
| Expenses | 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.75 |
| Operating Profit | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.75 |
| OPM % | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| Other Income | 0.01 | -0.00 | -0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 |
| Interest | 1.20 | 1.08 | 0.08 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -0.87 |
| Tax % | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | |
| Net Profit | 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -0.89 |
| EPS in Rs | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.48 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -247.83% | -75.00% | -521.01% | 88.23% | -43.68% | 6.40% | -277.78% | 96.83% | -650.00% | 20.95% | -8.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 172.83% | -446.01% | 609.24% | -131.91% | 50.08% | -284.18% | 374.61% | -746.83% | 670.95% | -29.39% |
MPS Pharmaa Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | -24% |
| 5 Years: | -44% |
| 3 Years: | -39% |
| Last Year: | -59% |
Last Updated: September 5, 2025, 3:51 pm
Balance Sheet
Last Updated: October 10, 2025, 4:21 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 5.05 | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 |
| Borrowings | 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 |
| Other Liabilities | 6.52 | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 |
| Total Liabilities | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 |
| Fixed Assets | 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 |
| CWIP | 0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 |
| Total Assets | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 |
Below is a detailed analysis of the balance sheet data for MPS Pharmaa Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 19.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 19.11 Cr..
- For Reserves, as of Mar 2025, the value is -18.03 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -17.14 Cr. (Mar 2024) to -18.03 Cr., marking a decline of 0.89 Cr..
- For Borrowings, as of Mar 2025, the value is 7.46 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 7.27 Cr. (Mar 2024) to 7.46 Cr., marking an increase of 0.19 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.80 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.70 Cr. (Mar 2024) to 0.80 Cr., marking an increase of 0.10 Cr..
- For Total Liabilities, as of Mar 2025, the value is 9.34 Cr.. The value appears to be improving (decreasing). It has decreased from 9.94 Cr. (Mar 2024) to 9.34 Cr., marking a decrease of 0.60 Cr..
- For Fixed Assets, as of Mar 2025, the value is 3.83 Cr.. The value appears to be declining and may need further review. It has decreased from 4.01 Cr. (Mar 2024) to 3.83 Cr., marking a decrease of 0.18 Cr..
- For CWIP, as of Mar 2025, the value is 2.91 Cr.. The value appears to be declining and may need further review. It has decreased from 3.26 Cr. (Mar 2024) to 2.91 Cr., marking a decrease of 0.35 Cr..
- For Investments, as of Mar 2025, the value is 0.54 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.54 Cr..
- For Other Assets, as of Mar 2025, the value is 2.06 Cr.. The value appears to be declining and may need further review. It has decreased from 2.13 Cr. (Mar 2024) to 2.06 Cr., marking a decrease of 0.07 Cr..
- For Total Assets, as of Mar 2025, the value is 9.34 Cr.. The value appears to be declining and may need further review. It has decreased from 9.94 Cr. (Mar 2024) to 9.34 Cr., marking a decrease of 0.60 Cr..
However, the Borrowings (7.46 Cr.) are higher than the Reserves (-18.03 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.38 | -6.97 | -7.14 | -9.78 | -3.43 | -3.24 | -3.20 | -9.82 | -6.49 | -7.72 | -8.07 | -8.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | |||||
| Inventory Days | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | ||||
| Days Payable | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | ||||
| Cash Conversion Cycle | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | |||||
| Working Capital Days | 99.72 | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | |||||
| ROCE % | 8.18% | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Diluted EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Cash EPS (Rs.) | -0.39 | -0.35 | -0.47 | 0.19 | -2.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| PBDIT / Share (Rs.) | -0.37 | -0.36 | -0.48 | -0.21 | -2.06 |
| PBIT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| PBT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| Net Profit / Share (Rs.) | -0.46 | -0.43 | -0.54 | -0.07 | -2.31 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -1290.32 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -2876.76 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -2880.22 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -437.31 | 0.00 |
| Return on Networth / Equity (%) | -83.09 | -42.21 | -37.63 | -3.70 | -111.78 |
| Return on Capital Employeed (%) | -68.25 | -38.85 | -35.47 | -22.83 | -96.84 |
| Return On Assets (%) | -9.62 | -8.36 | -10.31 | -1.39 | -39.07 |
| Total Debt / Equity (X) | 6.90 | 3.69 | 2.42 | 1.52 | 0.48 |
| Current Ratio (X) | 0.25 | 0.27 | 0.29 | 0.33 | 0.32 |
| Quick Ratio (X) | 0.19 | 0.20 | 0.22 | 0.24 | 0.24 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.08 | 0.03 | 0.00 |
| Interest Coverage Ratio (X) | -1433.20 | -563.32 | -1722.46 | -373.22 | -7579.04 |
| Interest Coverage Ratio (Post Tax) (X) | -1795.00 | -662.72 | -1955.76 | -125.49 | -8500.46 |
| Enterprise Value (Cr.) | 13.53 | 13.40 | 10.77 | 8.45 | 3.35 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 261.01 | 0.00 |
| EV / EBITDA (X) | -18.88 | -19.00 | -11.65 | -20.23 | -0.85 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 82.05 | 0.00 |
| Price / BV (X) | 5.63 | 3.12 | 1.44 | 0.69 | 0.36 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 86.88 | 0.00 |
| EarningsYield | -0.14 | -0.13 | -0.26 | -0.05 | -3.08 |
After reviewing the key financial ratios for MPS Pharmaa Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.39. This value is below the healthy minimum of 3. It has decreased from -0.35 (Mar 24) to -0.39, marking a decrease of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.37. This value is below the healthy minimum of 2. It has decreased from -0.36 (Mar 24) to -0.37, marking a decrease of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 2. It has decreased from -0.43 (Mar 24) to -0.46, marking a decrease of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -83.09. This value is below the healthy minimum of 15. It has decreased from -42.21 (Mar 24) to -83.09, marking a decrease of 40.88.
- For Return on Capital Employeed (%), as of Mar 25, the value is -68.25. This value is below the healthy minimum of 10. It has decreased from -38.85 (Mar 24) to -68.25, marking a decrease of 29.40.
- For Return On Assets (%), as of Mar 25, the value is -9.62. This value is below the healthy minimum of 5. It has decreased from -8.36 (Mar 24) to -9.62, marking a decrease of 1.26.
- For Total Debt / Equity (X), as of Mar 25, the value is 6.90. This value exceeds the healthy maximum of 1. It has increased from 3.69 (Mar 24) to 6.90, marking an increase of 3.21.
- For Current Ratio (X), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 1.5. It has decreased from 0.27 (Mar 24) to 0.25, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.20 (Mar 24) to 0.19, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1,433.20. This value is below the healthy minimum of 3. It has decreased from -563.32 (Mar 24) to -1,433.20, marking a decrease of 869.88.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1,795.00. This value is below the healthy minimum of 3. It has decreased from -662.72 (Mar 24) to -1,795.00, marking a decrease of 1,132.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.53. It has increased from 13.40 (Mar 24) to 13.53, marking an increase of 0.13.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -18.88. This value is below the healthy minimum of 5. It has increased from -19.00 (Mar 24) to -18.88, marking an increase of 0.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 5.63. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 5.63, marking an increase of 2.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.14. This value is below the healthy minimum of 5. It has decreased from -0.13 (Mar 24) to -0.14, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MPS Pharmaa Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -68.25% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -83.09% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1795
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.19
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 6.9
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 138, Roz-Ka-Meo Industrial Area, Mewat Dist. Haryana 122103 | info@mpspharmaa.com https://www.mpspharmaa.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Peeyush Kumar Aggarwal | Managing Director |
| Mr. Ram Niwas Sharma | Non Independent Director |
| Ms. Madhu Sharma | Independent Director |
| Mr. Ajay Sharma | Independent Director |
FAQ
What is the intrinsic value of MPS Pharmaa Ltd?
MPS Pharmaa Ltd's intrinsic value (as of 11 November 2025) is 4.12 which is 123.91% higher the current market price of 1.84, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3.52 Cr. market cap, FY2025-2026 high/low of 4.33/1.82, reserves of ₹-18.03 Cr, and liabilities of 9.34 Cr.
What is the Market Cap of MPS Pharmaa Ltd?
The Market Cap of MPS Pharmaa Ltd is 3.52 Cr..
What is the current Stock Price of MPS Pharmaa Ltd as on 11 November 2025?
The current stock price of MPS Pharmaa Ltd as on 11 November 2025 is 1.84.
What is the High / Low of MPS Pharmaa Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MPS Pharmaa Ltd stocks is 4.33/1.82.
What is the Stock P/E of MPS Pharmaa Ltd?
The Stock P/E of MPS Pharmaa Ltd is .
What is the Book Value of MPS Pharmaa Ltd?
The Book Value of MPS Pharmaa Ltd is 0.57.
What is the Dividend Yield of MPS Pharmaa Ltd?
The Dividend Yield of MPS Pharmaa Ltd is 0.00 %.
What is the ROCE of MPS Pharmaa Ltd?
The ROCE of MPS Pharmaa Ltd is 9.79 %.
What is the ROE of MPS Pharmaa Ltd?
The ROE of MPS Pharmaa Ltd is 59.0 %.
What is the Face Value of MPS Pharmaa Ltd?
The Face Value of MPS Pharmaa Ltd is 10.0.